Lethal combination

A combination of protein inhibitor and conventional anticancer drugs is proving effective in treating ovarian and breast cancer, according to a review by Susan Bates and Christina Annunziata of the National Cancer Institute in Bethesda, Maryland. Their review studied data on studies that took advantage of the synthetic lethality of BRCA (breast cancer susceptibility genes) and poly-ADP ribose polymerase (PARP) proteins to attack cancerous cells whilst sparing healthy ones. Bates notes that patients on combination therapy had improved "[disease] progression-free survival, and overall survival" as compared to patients treated with traditional drugs alone.